Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection

Journal of Hepatology

Volumn 32, Issue 2, 2000, Pages 269-278

  Khan, Khaleque Newaz ^a   Yatsuhashi, Hiroshi ^a,b   Yamasaki, Kazumi ^a   Yamasaki, Masafumi ^a   Inoue, Osami ^a   Koga, Michiaki ^a   Yano, Michitami ^a  

^a Nagasaki Chuo National Hospital   (Japan)

^b Hiroshi Yatsuhashi   (Japan)

Author keywords

Early recurrence; Hepatocellular carcinoma; Percutaneous ethanol injection; PIVKA II; Risk factors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALCOHOL; ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

EID: 0033953406     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80072-0     Document Type: Article

References (46)

1. Sugiura N, Takara K, Ohto M, Okuda K, Hirroka N. Treatment of small hepatocellular carcinoma by percutaneous injection of ethanol into tumor with real-time ultrasound monitoring. Acta Hepatol Jpn. 24:1983;920.
2. Ebara M, Ohto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, et al. Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: study of 95 patients. J Gastroenterol Hepatol. 5:1990;616-626.
3. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini GL, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis: a study in 207 patients. Cancer. 69:1992;925-929.
4. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 197:1995;101-108.
5. Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yoshiura K, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR. 160:1993;1023-1028.
6. Kotoh K, Sakai H, Sakamoto S, Nakayama S, Satoh M, Morotomi I, et al. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. Am J Gastroenterol. 89:1994;194-198.
7. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology. 18:1993;1121-1126.
8. Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 211:1990;28-33.
9. Jwo SC, Chiu JH, Chau GY, Loong CC, Lui WY. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology. 16:1992;1367-1371.
10. Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, et al. Incidence and risk factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 105:1993;488-494.
11. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamazaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology. 106:1994;1618-1624.
12. Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 106:1994;720-727.
13. Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology. 108:1995;768-775.
14. Pompili M, Rapaccini GL, de Luca F, Caturelli E, Astone A, Siena DA, et al. Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer. 79:1997;1501-1508.
15. Lencioni R, Bartolozzi C, Caramella D, Paolicchi A, Carrai M, Maltinti G, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: analysis of prognostic factors in 105 Western patients. Cancer. 76:1995;1737-1746.
16. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 25:1997;87-92.
17. Castellano L, Calandra M, Blanco CDV, de Sio I. Predictive factors of survival intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. J Hepatol. 27:1997;862-870.
18. Vilano R, Bruix J, Bru C, Ayuso MC, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology. 16:1992;353-357.
19. Edmonson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 7:1954;462-503.
20. Shiina S, Tagawa K, Unuma T, Terao A. Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma. AJR. 154:1990;947-951.
21. Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analysis. Hepatology. 14:1991;802-805.
22. Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, Takayama T, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer. 77:1996;1792-1796.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 63:1958;547-581.
24. Cox DR. Regression models and life tables. [with discussion] J R Stat Soc. 34:(series B):1972;187-220.
25. Yoshida Y, Kanematsu T, Matsumata T, Takenaka K, Sugimachi K. Surgical margin and recurrence after resection of hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 209:1989;297-301.
26. Nagasue N, Yukawa H, Ogawa Y, Sasaki Y, Chang YC, Niimi K. Second hepatic resection for recurrent hepatocellular carcinoma. Br J Surg. 73:1986;434-438.
27. Sasaki Y, Imaoka S, Fujita M, Miyoshi Y, Ohigashi H, Ishikawa O, et al. Regional therapy in the management of intrahepatic recurrence after surgery for hepatoma. Ann Surg. 206:1987;40-47.
28. Lin TY, Lee CS, Chen KM, Chen CC. Role of surgery in treatment of primary carcinoma of the liver: a 31-year experience. Br J Surg. 74:1987;839-842.
29. Ackerman NB, Nallathambi MN, Patel KR, Panchacharam P, Williams SE. Second hepatoma developing 13 years after resection of first tumor. Arch Surg. 121:1986;726-728.
30. Makuuchi M, Hasegawa H, Yamazaki S, Takayasu K, Moriyama N. The use of operative ultrasound as an aid to liver resection in patients with hepatocellular carcinoma. World J Surg. 11:1987;615-621.
31. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology. 27:1998;67-72.
32. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 18:1993;47-53.
33. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 12:1990;1420-1431.
34. Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, et al. Clinical significance of simultaneous determinations of alphafetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer. 77:1996;1781-1786.
35. Inoue S, Nakao A, Harada A, Nonami T, Takagi H. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol. 89:1994;2222-2226.
36. Huisse MG, Leclercq M, Belghiti J, Flejou JF, Suttie SJW, Bezeaud A, et al. Mechanism of the abnormal vitamin K-dependent γ-carboxylation process in human hepatocellular carcinoma. Cancer. 74:1994;1533-1541.
37. Suehiro T, Matsumata T, Itasaka H, Taketomi A, Yamamoto K, Sugimachi K. Des-gamma-carboxy prothrombin and proliferating activity of hepatocellular carcinoma. Surgery. 117:1995;682-691.
38. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma: comparison with alpha-fetoprotein. Cancer. 73:1994;2464-2471.
39. Chiu JH, Wu LH, Kao HL, Chang HM, Tsay SH, Loong CC, et al. Can determination of the proliferating capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular carcinoma? Hepatology. 18:1993;96-102.
40. Ling V. P-glycoprotein and resistance to anticancer drugs. Cancer. 69:1992;2603-2609.
41. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. L Natl Cancer Inst. 81:1989;116-124.
42. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug gene product (p-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 38:1990;1277-1287.
43. Nagasue N, Dhar DK, Makino Y, Yoshimura H, Nakamura T. Overexpression of P-glycoprotein in adenomatous hyperplasia of human liver with cirrhosis. J Hepatol; 22: 197-201.
44. Funaki NO, Tanaka J, Seto S-I, Kasamatsu T, Kaido T, Imamura M. Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology. 25:1997;564-568.
45. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 328:1993;1802-1806.
46. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med. 334:1996;1561-1567.